The global tyrosine protein kinase Fyn market is anticipated to grow at a significant CAGR 2.7% during the forecast period (2022-2028). Tyrosine-protein kinase Fyn is a non-receptor tyrosine. It plays an important role in the learning and memory of both animal models and human beings and is also responsible for other psychological disorders or mental problems such as schizophrenia, bipolar disorder, and depression, among others. The major factor driving the growth of the market is the increasing prevalence of breast cncer across the globe. 

According to the World Health Organization (WHO), breast cancer is the most common cancer globally accounting for 12% of all new annual cancer cases globally in 2021. Additionally, as per US Breast Cancer Statistics, about 1 in 8 US women or 13% will develop invasive breast cancer throughout their lifetime. Further, as per the same source, an estimated 287,850 new cases of invasive breast cancer are anticipated to be diagnosed in women in the US along with 51,400 new cases of non-invasive breast cancer in 2022.

Apart from this, tyrosine protein kinase Fyn drugs are used for treating metastatic and non-metastatic hormone receptor-positive or human epidermal growth factor receptor-positive. Additionally, it also used to treat patients with metastatic, hormone-receptor-positive breast cancer. Hence, the increasing prevalence of breast cancer is driving the demand for tyrosine protein kinase Fyn for treatment which in turn is driving the growth of the market. Moreover, North America is anticipated to hold a prominent share in the market due to the presence of disease such as cancer, Alzheimer, among others. Some major players in the market include Merck KGaA, AstraZeneca Plc, and Bristol-Myers Squibb Co., among others. 

Market Coverage

• The market number available for – 2021-2028

• Base year- 2021

• Forecast period- 2022-2028

• Segment Covered- 

o By Type

o By Application

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape- Merck KGaA, AstraZeneca Plc, and Bristol-Myers Squibb Co., among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How players are addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Tyrosine Protein Kinase Fyn Market Report by Segment

By Type

• Dasatinib

• Masitinib

• VAL-201

• Others

By Application 

• Alzheimer’s Disease

• Alcohol Addiction

• Breast Cancer

• Cancer Pain

• Others

Global Tyrosine Protein Kinase Fyn Market Report by Region

North America

• United States

• Canada

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa